Nucleolin inhibits Hdm2 by multiple pathways leading to p53 stabilization

被引:66
|
作者
Saxena, A.
Rorie, C. J.
Dimitrov, D.
Daniely, Y.
Borowiec, J. A.
机构
[1] NYU, Sch Med, Dept Biochem, New York, NY 10016 USA
[2] NYU, Sch Med, Inst Canc, New York, NY 10016 USA
关键词
ARF; Mdm2; nucleolin; p53; ubiquitination;
D O I
10.1038/sj.onc.1209714
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Nucleolin is a c-Myc-induced gene product with defined roles in ribosomal RNA processing and the inhibition of chromosomal DNA replication following stress. Here we find that changes in nucleolin protein levels in unstressed cells cause parallel changes in the amount of p53 protein. Alterations in p53 levels arise from nucleolin binding to the p53 antagonist Hdm2, resulting in the inhibition of both p53 ubiquitination and Hdm2 auto-ubiquitination. Nucleolin does not alter p53 ubiquitination by human papillomavirus E6, indicating that the effect is specific for Hdm2. Although the inhibition of ligase activity would be expected to stabilize Hdm2, we instead find that nucleolin also reduces Hdm2 protein levels, demonstrating that nucleolin inhibits Hdm2 using multiple mechanisms. Increases in nucleolin levels in unstressed cells led to higher expression of p21(cip1/waf1), a reduced rate of cellular proliferation, and an increase in apoptosis. Thus, nucleolin has a number of properties in common with the tumor suppressor ARF (alternate reading frame). We propose that nucleolin, like ARF, responds to hyperproliferative signals by upregulation of p53 through Hdm2 inhibition.
引用
收藏
页码:7274 / 7288
页数:15
相关论文
共 50 条
  • [31] A Highly Potent and Cellularly Active β-Peptidic Inhibitor of the p53/hDM2 Interaction
    Hintersteiner, Martin
    Kimmerlin, Thierry
    Garavel, Geraldine
    Schindler, Thorsten
    Bauer, Roman
    Meisner, Nicole-Claudia
    Seifert, Jan-Marcus
    Uhl, Volker
    Auer, Manfred
    CHEMBIOCHEM, 2009, 10 (06) : 994 - 998
  • [32] Deregulation of the p53/HDM2/p14ARF pathway in ductal adenocarcinomas of the pancreas
    Geradts, J
    Roberts, H
    Kern, S
    Hruban, R
    Wilentz, R
    MODERN PATHOLOGY, 2003, 16 (01) : 273A - 273A
  • [33] Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors
    Lai, ZH
    Yang, T
    Kim, YB
    Sielecki, TM
    Diamond, MA
    Strack, P
    Rolfe, M
    Caligiuri, M
    Benfield, PA
    Auger, KR
    Copeland, RA
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (23) : 14734 - 14739
  • [34] Deregulation of the p53/HDM2/p14ARF pathway in ductal adenocarcinomas of the pancreas
    Geradts, J
    Roberts, H
    Kern, S
    Hruban, R
    Wilentz, R
    LABORATORY INVESTIGATION, 2003, 83 (01) : 273A - 273A
  • [35] Human herpesvirus-6B protein U19 contains a p53 BOX I homology motif for HDM2 binding and p53 stabilization
    Kofod-Olsen, Emil
    Pettersson, Susanne
    Wallace, Maura
    Abduljabar, Ahmed Basim
    Oster, Bodil
    Hupp, Ted
    Hollsberg, Per
    VIROLOGY, 2014, 448 : 33 - 42
  • [36] Inhibitors of the p53/hdm2 protein-protein interaction-path to the clinic
    Carry, Jean-Christophe
    Garcia-Echeverria, Carlos
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (09) : 2480 - 2485
  • [37] hnRNP K: An HDM2 target and transcriptional coactivator of p53 in response to DNA damage
    Moumen, A
    Masterson, P
    O'Connor, MJ
    Jackson, SP
    CELL, 2005, 123 (06) : 1065 - 1078
  • [38] Nuclear and cytoplasmic degradation of endogenous p53 and HDM2 occurs during down-regulation of the p53 response after multiple types of DNA damage
    Joseph, TW
    Zaika, A
    Moll, UM
    FASEB JOURNAL, 2003, 17 (12): : 1622 - 1630
  • [39] AURKA-mediated Activation of HDM2 Regulates p53 in Upper Gastrointestinal Cancers
    Sehdev, Vikas
    Katsha, Ahmed M.
    Peng, DunFa
    Belkhiri, Abbes
    Soutto, Mohammed
    Ecsedy, Jeffrey
    Zaika, Alexander
    El-Rifai, Wael
    GASTROENTEROLOGY, 2013, 144 (05) : S167 - S167
  • [40] Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2
    Kitagaki, Jirouta
    Agama, Keli K.
    Pommier, Yves
    Yang, Yili
    Weissman, Allan M.
    MOLECULAR CANCER THERAPEUTICS, 2008, 7 (08) : 2445 - 2454